Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 483-489

  Gerra, G ^a   Saenz, E ^a   Busse, A ^a   Maremmani, I ^b   Ciccocioppo, R ^c   Zaimovic, A ^d   Gerra, M L ^e   Amore, M ^e   Manfredini, M ^e   Donnini, C ^e   Somaini, L ^f  

^a United Nations Office on Drugs and Crime Austria   (Austria)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF CAMERINO   (Italy)

^d AUSL Parma   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f Dipartimento Dipendenze Health Local Unit BI   (Italy)

Author keywords

Contingent take home; Methadone; Non contingent take home

Indexed keywords

DIAMORPHINE; METHADONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BORDERLINE STATE; CLINICAL PROTOCOL; CONTINGENT TAKE HOME INCENTIVE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRIMINAL BEHAVIOR; DEPRESSION; FEMALE; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON CONTINGENT TAKE HOME; OBSERVATIONAL STUDY; OBSESSIVE COMPULSIVE DISORDER; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PSYCHOPATHY; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SELF REPORT; SUPERVISED DAILY CONSUMPTION; URINALYSIS; VIOLENCE;

ANALGESICS, OPIOID; COMORBIDITY; CRIME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; MENTAL DISORDERS; METHADONE; MOTIVATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; SELF REPORT; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIOLENCE;

EID: 79952902675     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.12.002     Document Type: Article

References (36)

1. Anstice S., Strike C.J., Brands B. Supervised methadone consumption: client issues and stigma. Subst Use Misuse 2009, 44(6):794-808.
2. Auriacombe M, Fatseas M, Franques-Rénéric P, Daulouède JP, Tignol J. Substitution therapy in drug addictions. Rev Prat 2003;53(12):1327-34 [Review. French].
3. Avants S.K., Margolin A., Sindelar J.L., Rounsaville B.J., Schottenfeld R., Stine S., et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry 1999, 156(1):27-33.
4. Bell J., Zador D.A. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000, 22:179-190.
5. Breslin K.T., Malone S. Maintaining the viability and safety of the methadone maintenance treatment program. J Psychoactive Drugs 2006, 38:157-160.
6. Chutuape M.A., Silverman K., Stitzer M.L. Use of methadone take-home contingencies with persistent opiate and cocaine abusers. J Subst Abuse Treat 1999, 16(1):23-30.
7. Cicero T.J. Diversion and abuse of methadone prescribed for pain management. JAMA 2005, 293:297-298.
8. College of Physicians Surgeons of Ontario Methadone Maintenance Guidelines 2005.
9. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007, 11(9):1-171.
10. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008, 165(2):179-187.
11. Fava M., Guaraldi G.B., Mazzi F., Rigatelli M. Intervista Clinica Strutturata per il DSM-III-R 1993, Organizzazioni Speciali, Florence.
12. Fountain J., Strang J., Gossop M., Farrell M., Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000, 95:393-406.
13. Green H.B., James R.A., Gilbert J.D., Harpas P.B., Byard R.W. Methadone maintenance programs-a two edged sword?. Am J Forensic Med Pathol 2000, 21:359-361.
14. Hutchinson S.J., Taylor A., Gruer L., Barr C., Mills C., Elliott L., et al. One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. Addiction 2000, 95(7):1055-1068.
15. Jasinski D.R., Preston K.L. Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 1986, 17(4):301-310.
16. Kidorf M., Stitzer M.L., Brooner R.K., Goldberg J. Contingent methadone take-home doses reinforce adjunct therapy attendance of methadone maintenance patients. Drug Alcohol Depend 1994, 36(3):221-226.
17. King V.L., Kidorf M.S., Stoller K.B., Schwartz R., Kolodner K., Brooner R.K. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J Subst Abuse Treat 2006, 31(4):385-393.
18. Kreek M.J. Methadone-related opioid agonist pharmacotherapy for heroin addiction.History, recent molecular and neurochemical research and future in mainstream medicine. Ann NY Acad Sci 2000, 909:186-216.
19. Lewis D. Credibility, support for methadone treatment-finally. Brown Univ Dig Addict Theory Appl 1997, 16. n12 (1).
20. Luger L., Bathia N., Alcorn R., Power R. Involvement of community pharmacists in the care of drug misusers: pharmacy-based supervision of methadone consumption. Int J Drug Policy 2000, 11(3):227-234.
21. Maffei C., Fossati A., Agostoni I., Barraco A., Bagnato M., Deborah D., et al. Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. J Pers Disord 1997, 11:279-284.
22. Maremmani I., Zolesi O., Aglietti M., Marini G., Tagliamonte A., Shinderman M., et al. Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis 2000, 19(2):29-41.
23. Pfohl B., Blum N., Zimmerman M., Stangl D. Structured Interview for Personality Disorders, revised version 1989, University of Iowa, Iowa City, IA.
24. Radcliffe P., Stevens A. Are drug treatment service only for "thieving junkie scumbags"? Drug users and the management of stigmatised identities. Soc Sci Med 2008, 67(7):1065-1073.
25. Rhoades H.M., Creson D., Elk R., Schmitz J., Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998, 88(1):34-39.
26. Ritter A., Di Natalie R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev 2005, 24:347-352.
27. Rogers R.E., Higgins S.T., Silverman K., Thomas C.S., Badger G.J., Bigelow G., et al. Abstinence-contingent reinforcement and engagement in non-drug-related activities among illicit drug abusers. Psychol Addict Behav 2008, 22(4):544-550.
28. Schmitz J.M., Rhoades H.M., Elk R., Creson D., Hussein I., Grabowsk J. Medication take-home doses and contingency management. Exp Clin Psychopharmacol 1998, 6(2):162-168.
29. Sees K.L., Delucchi K.L., Masson C., Rosen A., Clark H.W., Robillard H., et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000, 283(10):1303-1310.
30. Seymour A., Black M., Jay J., Cooper G., Weir C., Oliver J. The role of methadone in drug-related deaths in the west of Scotland. Addiction 2003, 98:995-1002.
31. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview According to DSM-III-R 1990, American Psychiatric Press, Washington, DC.
32. Stitzer M.L., Vandrey R. Contingent management: utility in the treatment of drug abuse disorders. Clin Pharmacol Ther 2008, 83(4):644-647.
33. Stone E., Fletcher K. User views on supervised methadone consumption. Addict Biol 2003, 8(1):45-48.
34. Varenbut M., Teplin D., Daiter J., Raz B., Worster A., Emadi-Konjin P., et al. Tampering by office-based methadone maintenance patients with methadone take home privileges: a pilot study. Harm Reduct J 2007, 4:15.
35. Zaller N.D., Bazazi A.R., Velazquez L., Rich J.D. Attitudes toward methadone among out-off-treatment minority injection drug users: implication for health disparities. Int J Environ Res Public Health 2009, 6(2):787-797.
36. White J.M., Ryan C.F., Ali R.L. Improvements in retention rates and changes in client group with methadone maintenance streaming. Drug Alcohol Rev 1996, 15(1):83-88.